ms. martello, you are recognized. >> chairman bono mack, ranking member butterfield and distinguished members of the subcommittee, my name is kendra martello and i'm pleased to offer this testimony on behalf of the pharmaceutical research and manufacturers of america or farma. our members represent america's leading pharmaceutical research and biotechnology companies. our prescription drug distribution system is a closed system. this means that all entities engaged in the manufacture, distribution and distensing of pharmaceutical products including controlled substances must be licensed, registered or approved by f by fda, dea or the stat states. when an authentic ro duct is diverted, it could be mishandled and potentially cause patient harm if reintroduced into the legitimate supply chain. additionally the divertsed medicine can be misused or abused. the controlled substances act and dea regulations require entities handling the products to register and have in place effective controls and security measures to protect against theft, loss or diversion of controlled substances. the dea also ha